AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:17 2024-09-17 am EDT			5-day change	1st Jan Change
11,968.00 ^GBX	-0.40%		-3.53%	+12.91%

Sep. 17	REGENXBIO Inc. Announces Chief Financial Officer Changes	CI
Sep. 17	REGENXBIO Inc. Announces Executive Changes	CI

AstraZeneca prices EUR1.4 billion in bonds at 3.1% and 3.3%

July 30, 2024 at 11:00 am EDT

AstraZeneca PLC - Cambridge, England-based biopharmaceutical maker - Prices two tranches of eurobonds, raising a total of EUR1.40 billion for "general corporate purposes". Issues EUR650 million in fixed-rate notes with a coupon of 3.121% maturing in August 2030, and EUR750 million in fixed-rate notes with a coupon of 3.278% maturing in August 2033. The offering, by subsidiary AstraZeneca Finance LLC, is run by BNP Paribas, Goldman Sachs International, Morgan Stanley and Societe Genarale as joint book-running managers.

Current stock price: 12,259.34 pence, down 0.9% in London on Tuesday

12-month change: up 9.6%

By Tom Waite, Alliance News editor

Comments and questions to newsroom@alliancenews.com

Stocks mentioned in the article

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
ASTRAZENECA PLC	11,968.00 GBX	-0.40%	-3.53%	246B
THE GOLDMAN SACHS GROUP, INC.	485.39 USD	+0.05%	+3.91%	162B
MORGAN STANLEY	99.84 USD	-0.25%	+3.33%	162B
BNP PARIBAS	64.45 EUR	+1.83%	+3.00%	79.55B
SOCIÉTÉ GÉNÉRALE	22.62 EUR	+1.53%	+2.56%	19.78B

Latest news about AstraZeneca PLC

REGENXBIO Inc. Announces Chief Financial Officer Changes	Sep. 17	CI
REGENXBIO Inc. Announces Executive Changes	Sep. 17	CI
ASTRAZENECA : JP Morgan keeps its Buy rating	Sep. 17	ZD
Sanofi, AstraZeneca Win US Approval for New RSV Vaccine Manufacturing Line	Sep. 16	MT
European Equities Close Mostly Lower in Monday Trading; Deutsche Bank Aims to Block UniCredit From Buying Commerzbank Stake	Sep. 16	MT
Sanofi Shipping Beyfortus in US Ahead of Respiratory Syncytial Virus Disease Season	Sep. 16	MT
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell as Investors Mull Possible Rate Cut	Sep. 16	MT
AstraZeneca Says Hepatocellular Carcinoma Combination Therapy Trial Showed 'Sustained, Clinically Meaningful Overall Survival Benefit' at 5 Years	Sep. 16	MT
AstraZeneca: several positive results in cancer	Sep. 16	CF
AstraZeneca celebrates survival rate of Imfinzi-Imjudo mix	Sep. 16	AN
AstraZeneca's Trial Shows IMFINZI Reduces Risk of Recurrence, Death in Patients With Bladder Cancer	Sep. 16	MT
AstraZeneca's Imfinzi Combination Shows Sustained Survival Rate at Five-year Follow-up	Sep. 16	MT
ASTRAZENECA : UBS reiterates its Sell rating	Sep. 16	ZD
AstraZeneca Reports Positive Results from Trial of Imfinzi in Muscle-invasive Bladder Cancer	Sep. 16	MT
AstraZeneca Announces Positive Results from the Niagara Phase III Trial	Sep. 15	CI
SOPHiA GENETICS Presents Multimodal Research on AI-Driven Patient Stratification at ESMO 2024	Sep. 14	CI
AstraZeneca, Daiichi Sankyo Breast Cancer Drug Trial Shows 'Substantial Clinical Activity'	Sep. 13	MT
Daiichi, Astra's Enhertu shows clinical activity in brain metastases	Sep. 13	AN
Stocks up as market raises bets on bumper US cut	Sep. 13	AN
AstraZeneca, Daiichi Sankyo Reports Safety Profile of Breast Cancer Drug in Phase 3b/4 Study	Sep. 13	MT
Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases	Sep. 13	CI
A central bank and it's off again?	Sep. 13
Deutsche Bank Downgrades AstraZeneca to Sell From Hold	Sep. 13	MT
ASTRAZENECA : Deutsche Bank upgrades to 'sell'.	Sep. 13	CF
Deutsche Bank Downgrades AstraZeneca to Sell, Trims PT	Sep. 13	MT

Chart AstraZeneca PLC

Duration

Period

More charts

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

2024-09-17 - Bank of America Global Healthcare Conference

More about the company